Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Nathan Pennell, MD, PhD, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00970684
First received: September 1, 2009
Last updated: December 18, 2013
Last verified: December 2013

September 1, 2009
December 18, 2013
September 2009
September 2011   (final data collection date for primary outcome measure)
Progression Free Survival(PFS) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
PFS is defined as time to death or first occurrence of documented disease progression assessed by the investigator as per the RECIST guidelines (at lease a 20% increase in the diameter of a lesion, in addition to an absolute increase of 5mm). If no deaths occur prior to progression, this measure will be the same as the median time to progression.
1-year progression-free survival rate [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00970684 on ClinicalTrials.gov Archive Site
  • Median Time to Progression [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Time to progression (TTP) is defined as the time from start of treatment to first evidence of disease progression, defined per the RECIST 1.1 criteria as at least a 20% increase in the diameter of a lesion and an absolute increase of at least 5mm.
  • Best Response [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The number of patients with a response will be assessed using the RECIST criteria of complete response (the disappearance of all target lesions); partial response (at least a 30% decrease in the diameter of lesions); progressive disease at least a 20% increase in the diameter of lesions); or stable disease(neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease)
  • Median time to progression [ Designated as safety issue: No ]
  • Response rate as measured by RECIST criteria [ Designated as safety issue: No ]
  • Median overall survival [ Designated as safety issue: No ]
  • Adverse events [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with docetaxel and gemcitabine hydrochloride may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel and gemcitabine hydrochloride works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

OBJECTIVES:

Primary

  • Estimate the 1-year progression-free survival rate in patients with stage IIIB, stage IV, or recurrent non-squamous cell non-small cell lung cancer treated with bevacizumab, docetaxel, and gemcitabine hydrochloride.

Secondary

  • Evaluate the median time to progression in patients treated with this regimen.
  • Estimate the response rate in patients treated with this regimen.
  • Determine the median overall survival of patients treated with this regimen.
  • Determine the incidence of adverse events associated with this regimen in these patients.

OUTLINE: Patients receive bevacizumab IV over 30-90 minutes and docetaxel IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease may then continue to receive bevacizumab alone for up to 12 months in the absence of disease progression.

After completion of study treatment, patients are followed up every 3 months.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
  • Biological: bevacizumab
    15 mg/kg on day 1 of a 21-day cycle
    Other Name: bevacizumab
  • Drug: docetaxel
    75 mg/m2 on day 1
    Other Name: docetaxel
  • Drug: gemcitabine hydrochloride
    900 mg/m2 on days 1, and 8,
    Other Name: gemcitabine hydrochloride
Experimental: Bevacizumab, Docetaxel, and Gemcitabine
Treatment repeats every 21 days for up to 6 courses.
Interventions:
  • Biological: bevacizumab
  • Drug: docetaxel
  • Drug: gemcitabine hydrochloride
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13
September 2011
September 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed non-squamous cell non-small cell lung cancer

    • Stage IIIB (with pleural effusion), stage IV, or recurrent disease
  • Bidimensionally measurable disease
  • No known CNS disease, except for previously treated brain metastasis defined as no evidence of progression or hemorrhage after treatment AND no ongoing requirement for dexamethasone as documented by clinical examination, MRI, or CT scan

    • Treatment for brain metastases may have included whole brain radiotherapy, radiosurgery (gamma knife, LINAC, or equivalent), or a combination of therapy as deemed appropriate by the treating physician
    • Stable dose of anticonvulsants allowed
  • No known metastatic disease to the gastrointestinal tract (e.g., stomach, small bowel, or large bowel)

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-1
  • Life expectancy > 3 months
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9 g/dL
  • Bilirubin ≤ 2.0 mg/dL
  • AST or ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5.0 times ULN if hepatic metastases are present)
  • Serum creatinine ≤ 1.8 mg/dL
  • Urine protein:creatinine ratio < 1.0 OR proteinuria < 2+ by urine dipstick OR ≤ 1 g of protein by 24-hour urine collection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Available for regular follow-ups
  • No inadequately controlled hypertension, defined as systolic BP > 150 mm Hg and/or diastolic BP > 100 mm Hg despite antihypertensive medications
  • No history of hypertensive crisis or hypertensive encephalopathy
  • No NYHA class II-IV congestive heart failure
  • No myocardial infarction or unstable angina within the past 6 months
  • No stroke or transient ischemic attack within the past 6 months
  • No significant vascular disease (e.g., aortic aneurysm, aortic dissection requiring surgical repair, or recent peripheral arterial thrombosis) within the past 6 months
  • No symptomatic peripheral vascular disease
  • No evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  • No history of colonic diverticular disease (i.e., diverticulosis or diverticulitis)
  • No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No serious, nonhealing wound, ulcer, or bone fracture
  • No known hypersensitivity to any component of bevacizumab
  • No hemoptysis (bright red blood of ≥ ½ teaspoon per episode) within the past 3 months
  • No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior chemotherapy or biological therapy
  • No prior radiotherapy to an area of measurable disease unless there is documented progressive disease after completion of therapy
  • More than 2 weeks since prior radiotherapy
  • More than 4 weeks since prior and no concurrent participation in another experimental drug study, except for a Genentech-sponsored bevacizumab cancer study
  • More than 28 days since prior major surgical procedure or open biopsy
  • More than 3 months since prior abdominal surgery
  • More than 3 months since prior neurosurgical resection or brain biopsy
  • More than 7 days since prior core biopsy or other minor surgical procedure, except placement of a vascular access device
  • No concurrent major surgical procedure
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00970684
CASE4507, P30CA043703, CASE4507, CASE 4507-CC694, NCI-2010-00547
Yes
Nathan Pennell, MD, PhD, Case Comprehensive Cancer Center
Nathan Pennell, MD, PhD
National Cancer Institute (NCI)
Principal Investigator: Nathan Pennell, MD, PhD Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Principal Investigator: Afshin Dowlati, MD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP